Genetically Modified Immune Effector Cells Show Long-Term Safety in Study
Thirteen patients in a cohort of 340 cancer patients who received genetically modified immune cells developed 16 secondary cancers in the months or years following treatment, a rate comparable to patients who receive standard-of-care therapies, including chemotherapy and hematopoietic stem cell transplant. Researchers reviewed biopsy results for 11 of the secondary tumors and found no transferred genetic material from the therapy.
United States David Steffin Ibrahim Muhsen Development Of Subsequent Malignancies In Patients Gene Therapy At Baylor College Of Medicine Gene Therapy
Source: genengnews.com